Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Magnetic pulses aim to boost heart health in blocked arteries

NCT ID NCT05111288

Disease control Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 10, 2026 · Updated 2 times

Summary

This study tests whether a device called Bioboosti, which delivers pulsed electromagnetic fields, can improve blood flow to the heart in people with coronary artery disease. Researchers will measure blood flow during stress and track symptoms like chest pain and exercise capacity. The study involves 120 participants who cannot undergo standard artery-opening procedures.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Pulsed electromagnetic field therapy (PEMF) device
What this could lead to
If it works, this could offer a noninvasive way to improve blood flow to the heart for people with coronary artery disease who cannot have standard procedures.
What could go wrong
This is an early study with only 120 participants, and it uses a sham device for comparison. The treatment may not improve blood flow or symptoms, and results may not apply to all heart patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2022

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years old. * Known cardiac ischemia, who are non revascularizable, or have not and will not be undergo coronary intervention for the duration of their participation in the study. * Evidence of ischemia from previous clinical tests (echo, nuclear, standard ECG from past 6 months). * Left Ventricular Ejection fraction \> 40% by echo (evaluated last 3 months). * Able to complete a cardiopulmonary exercise test without significant non cardiac limitations, primarily orthopedic. * On guideline directed optimal therapy for stable ischemia. Exclusion Criteria: * Anemia (\< 7 mg/dl). * Low potassium (\< 3 mmol/L). * Creatinine (\> 5.0 mg/dl or \< 0.6 mg/dl). * Unable to exercise due primarily to orthopedic limitation. * Severe lung disease. * Morbid obesity (BMI \> 42). * Pregnant. * Breast feeding. * Significant arrhythmia (ventricular tachycardia, ventricular fibrillation, frequent premature ventricular contractions (PVCs), persistent atrial fibrillation, or 2nd or 3rd degree atrioventricular (AV) block). * Seizures. * Unstable angina. * Coronary spasm. * Recent myocardial infarction (\< 90 days). * Recent percutaneous coronary intervention (\<90 days).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronary artery disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary artery disorder myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coronary artery disease Myocardial infarction

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Mayo Clinic in Arizona

    RECRUITING

    Scottsdale, Arizona, 85259, United States

  • Mayo Clinic in Rochester

    RECRUITING

    Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.